Table 2.

Least-squares mean change (95% CI) in efficacy endpoints during the OLE (OLE analysis set)

	Ravulizumab–ravulizumaba (n = 78)			Placebo–ravulizumabb (n = 83)
	RCP baseline to Week 60 (OLE Week 34)	OLE baseline to Week 60 (OLE Week 34)		RCP baseline to Week 60 (OLE Week 34)	OLE baseline to OLE Week 2 or 4c	OLE baseline to Week 60 (OLE Week 34)
MG-ADL total score	− 4.0 (− 4.8, − 3.1)  p < 0.0001	− 0.3 (− 0.9, 0.3)  p = 0.3095		− 3.3 (− 4.3, − 2.2)  p < 0.0001	− 1.7 (− 2.4, − 1.0)  p < 0.0001	− 1.7 (− 2.7, − 0.8)  p = 0.0007
QMG total score	− 4.1 (− 5.4, − 2.9)  p < 0.0001	− 0.9 (− 1.9, 0.0)  p = 0.0555		− 3.8 (− 5.1, − 2.4)  p < 0.0001	− 2.1 (− 3.0, − 1.1)  p < 0.0001	− 3.1 (− 4.2, − 1.9)  p < 0.0001
MG-QOL15r total score	− 5.0 (− 6.9, − 3.1)  p < 0.0001	− 0.8 (− 1.8, 0.3)  p = 0.1562		− 5.4 (− 7.3, − 3.5)  p < 0.0001	− 3.5 (− 5.1, − 1.9)  p < 0.0001	− 3.1 (− 4.8, − 1.4)  p = 0.0005
Neuro-QoL Fatigue total score	− 10.2 (− 15.1, − 5.3)  p < 0.0001	− 1.5 (− 5.0, 1.9)  p = 0.3831		− 14.0 (− 18.6, − 9.4)  p < 0.0001	− 9.3 (− 13.7, − 5.0)  p < 0.0001	− 8.0 (− 12.3, − 3.6)  p = 0.0005

CI, confidence interval; MG-ADL, Myasthenia Gravis–Activities of Daily Living; MG-QOL15r, revised 15-item Myasthenia Gravis Quality of Life; Neuro-QoL, Neurological Quality of Life; OLE, open-label extension; QMG, Quantitative Myasthenia Gravis; RCP, randomized controlled period

^aPatients treated with ravulizumab during both the RCP and OLE. ^bPatients treated with placebo during the RCP and ravulizumab during the OLE. ^cOLE Week 2 for MG-ADL and QMG scores, OLE Week 4 for MG-QOL15r and Neuro-QoL Fatigue scores